These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. The Treatment of Primary Orthostatic Hypotension. Hale GM, Valdes J, Brenner M. Ann Pharmacother; 2017 May; 51(5):417-428. PubMed ID: 28092986 [Abstract] [Full Text] [Related]
4. Efficacy of atomoxetine versus midodrine for neurogenic orthostatic hypotension. Byun JI, Kim DY, Moon J, Shin HR, Sunwoo JS, Lee WJ, Lee HS, Park KI, Lee ST, Jung KH, Jung KY, Kim M, Lee SK, Chu K. Ann Clin Transl Neurol; 2020 Jan; 7(1):112-120. PubMed ID: 31856425 [Abstract] [Full Text] [Related]
5. Evaluating the effectiveness of atomoxetine for the treatment of primary orthostatic hypotension in adults. Patel H, Simpson A, Palevoda G, Hale GM. J Clin Hypertens (Greenwich); 2018 Apr; 20(4):794-797. PubMed ID: 29569329 [No Abstract] [Full Text] [Related]
6. Synergistic Pressor Effect of Atomoxetine and Pyridostigmine in Patients With Neurogenic Orthostatic Hypotension. Okamoto LE, Shibao CA, Gamboa A, Diedrich A, Raj SR, Black BK, Robertson D, Biaggioni I. Hypertension; 2019 Jan; 73(1):235-241. PubMed ID: 30571543 [Abstract] [Full Text] [Related]
11. Managed care approach to the treatment of neurogenic orthostatic hypotension. Isaacson SH. Am J Manag Care; 2015 Oct; 21(13 Suppl):s258-68. PubMed ID: 26790110 [Abstract] [Full Text] [Related]
12. Clinical benefit of midodrine hydrochloride in symptomatic orthostatic hypotension: a phase 4, double-blind, placebo-controlled, randomized, tilt-table study. Smith W, Wan H, Much D, Robinson AG, Martin P. Clin Auton Res; 2016 Aug; 26(4):269-77. PubMed ID: 27372462 [Abstract] [Full Text] [Related]
13. [Arterial hypotension: behind the scenes]. Roukain A, Pechere-Bertschi A. Rev Med Suisse; 2018 Sep 12; 14(618):1581-1587. PubMed ID: 30226654 [Abstract] [Full Text] [Related]
14. Efficacy of single or combined midodrine and pyridostigmine in orthostatic hypotension. Byun JI, Moon J, Kim DY, Shin H, Sunwoo JS, Lim JA, Kim TJ, Lee WJ, Lee HS, Jun JS, Park KI, Lee ST, Jung KH, Jung KY, Lee SK, Chu K. Neurology; 2017 Sep 05; 89(10):1078-1086. PubMed ID: 28794253 [Abstract] [Full Text] [Related]
15. Randomized withdrawal study of patients with symptomatic neurogenic orthostatic hypotension responsive to droxidopa. Biaggioni I, Freeman R, Mathias CJ, Low P, Hewitt LA, Kaufmann H, Droxidopa 302 Investigators. Hypertension; 2015 Jan 05; 65(1):101-7. PubMed ID: 25350981 [Abstract] [Full Text] [Related]
16. Midodrine in neurogenic orthostatic hypotension. A new treatment. Gilden JL. Int Angiol; 1993 Jun 05; 12(2):125-31. PubMed ID: 7690383 [Abstract] [Full Text] [Related]
18. Pyridostigmine bromide versus fludrocortisone in the treatment of orthostatic hypotension in Parkinson's disease - a randomized controlled trial. Schreglmann SR, Büchele F, Sommerauer M, Epprecht L, Kägi G, Hägele-Link S, Götze O, Zimmerli L, Waldvogel D, Baumann CR. Eur J Neurol; 2017 Apr 05; 24(4):545-551. PubMed ID: 28224720 [Abstract] [Full Text] [Related]
19. Synergistic effect of norepinephrine transporter blockade and α-2 antagonism on blood pressure in autonomic failure. Okamoto LE, Shibao C, Gamboa A, Choi L, Diedrich A, Raj SR, Black BK, Robertson D, Biaggioni I. Hypertension; 2012 Mar 05; 59(3):650-6. PubMed ID: 22311903 [Abstract] [Full Text] [Related]
20. Effectiveness of droxidopa compared to midodrine in standing blood pressure and orthostatic tolerance in adults with neurogenic orthostatic hypotension: a systematic review protocol. Patrick K, Martin T. JBI Database System Rev Implement Rep; 2017 Sep 05; 15(9):2287-2294. PubMed ID: 28902695 [Abstract] [Full Text] [Related] Page: [Next] [New Search]